| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.02 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.02 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |